Your Shopping Cart
By using this site you agree to our use of cookies. Please refer to our privacy policy for more information. Close
Hello. Sign In
Your Account

Log In to ComplianceOnline
Welcome back! Please log in below to continue.
0
Cart
Toll Free:
+1-888-717-2436
+1-888-717-2436
Industries
- Banking & Financial Services
- BANKING & FINANCIAL SERVICES
- Banks and Credit Unions
- Financial Services and Trading
- Insurance
- Accounting and Taxation
- Life Sciences
- Hitech, Aero & Manufacturing
- HITECH, AERO & MANUFACTURING
- Quality & Safety
- Standards and Methodology
- Energy & Utilities
- ENERGY & UTILITIES
- IT Security
- Reliability (NERC / FERC)
- Quality and Safety
- Risk Management
- CPG & Retail
- CPG & RETAIL
- Retail Audit
- Quality & Safety
- Social Compliance
- Healthcare
- Food & Dietary Supplements
- Cross Industry Functions
Webinars
By Industries
Seminars
Method Development and Validation for Assays Supporting Testing of Biologics
Cleanroom, Microbiology and Sterility Assurance Practices for Drug and Device...
Preparing for FDA's New Import/Export Trauma in 2020
Introduction into the EU IVDR 2017/746 - the new EU regulation for invitro diagno...
Fundamentals of EU MDR and IVDR – Level 1
Analytical Instrument Qualification and System Validation
REACH and RoHS Compliance: Gain a Deeper Understanding
Why is FDA at my facility, and what do I do during an inspection?
Ensuring Compliance with Advertising and Promotional Requirements for Drugs...
Managing Your Complaints and Obstacles in Post-Market Requirements -- Results...
Sexual Harassment Certificate Program for HR Professionals
OSHA and Workers Compensation Certificate Program
FMLA, ADA and PDA Certificate Program
Employment Laws Certificate Program for HR Professionals, Managers and Super...
Project Management for Human Resources
How to Conduct a Workplace Harassment, Bullying & Violence Investigations Tra...
Data Integrity: FDA/EU Requirements and Implementation
Operations Risk Management and Mitigation - from assessment to implementation
Technical Writing for Pharma, Biotech and Medical Devices
Risk Based Internal Auditing (RBIA)
Lifecycle Management of Analytical Methods and Procedures - according to new...
Validation, Verification and Transfer of Analytical Methods (Understanding and...
Standards
Aerospace
Agriculture and Farm Machinery
Automotive, Aircraft & Marine technology
Banking, Corp. finance & Sox
Biotech & Pharmaceutical Standards
Chemical technology
Civil engineering and construction
Computer Hardware
Electrical Engineering
Electronic Equipment
ANSI
Audit Net
BIN
BPA
Business Basics
Complianceonline
IT Governance
LabCompliance
Quality-Control-Plan
RCGLOBAL
SHOQ Quality Assurance Manuals
Superfactory
22000-Tools by Vinca, LLC
Home
› Best Practices
FDA Decree Results into Shares Fall for Genzyme
- Date: March 26, 2010
- Source: Admin
Genzyme and Its Fouled Situation
From last year, Genzyme is facing quite a tough time. A viral contamination led to the shutdown of its Boston plant and at the same time forced it to restructure and refurbish the manufacturing process. Moreover, during the process Genzyme had to replace and cancel production contract of some of its drugs such as Cerezyme and Fabrazyme, which resulted into global shortage of medicines.
This year on March 23, FDA informed that it would install a third party group “for an extended period" to inspect, review and certify the drugs produced at the Boston plant, where the FDA had in November found traces of pollutants, including steel and rubber. Moreover, the agent announced that it may require to the company to make payments to the government. As a result of the announcement made by the FDA, it is assumed, Genzyme shares fell down abruptly.
In a statement Wednesday, the company assured to "work cooperatively with the FDA to restore the agency's confidence in its ability to operate the Allston plant at the highest standards, building on the progress it has made over the past year to address the manufacturing deficiencies."
However, Genzyme is still unaware of the financial upshots of the declaration but the company assures that the FDA demands will not cause the Gaucher and Fabry disease medications to fall out of production for a second time. Genzyme has only recently brought production of the Gaucher treatment up to normal levels after it too was scarce for the second half of 2009. The company is also hoping that the agency’s action doesn’t interrupt finishing work at the plant on alglucosidase alfa (Myozyme), a Pompe disease therapy, and thyrotropin alfa (Thyrogen), which is used in patients with thyroid cancer.
Source:
http://www.thestreet.com/story/10710726/1/genzyme-shares-fall-on-fda-action.html?puc=_tscrss
http://www.transworldnews.com/NewsStory.aspx?id=286484&cat=1
Compliance Trainings

Pregnancy in the Workplace: Strategies to Protect Your Organization from Pregnancy Discrimination Claims
By - Christopher W. Olmsted
On Demand Access Anytime
By - Christopher W. Olmsted
On Demand Access Anytime

How to Vet an IRB: Expose and Fix Problems Before They Threaten Your Trial
By - Madhavi Diwanji
On Demand Access Anytime
By - Madhavi Diwanji
On Demand Access Anytime

Compliance Standards
Best Sellers
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
-
By: Miles HutchinsonAdd to CartPrice: $149
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
-
Tampa, FL | Apr 2-3, 2020
-
Orlando, FL | Mar 19-20, 2020
-
Greenville, SC | Jan 8-9, 2020
-
Charlotte, NC | Jan 22-24, 2020
-
Boston, MA | Apr 16-17, 2020
-
San Francisco, CA | Mar 26-27, 2020
-
Minneapolis, MN | Jan 30-31, 2020
-
Scottsdale, AZ | Feb 26-27, 2020
-
Houston, TX | Jan 30-31, 2020
-
San Francisco, CA | Feb 6-7, 2020
-
London, UK | Dec 12-13, 2019
-
Salt Lake City, UT | Feb 20-21, 2020
-
St. Louis, MO | Jan 23-24, 2020
-
San Diego, CA | Feb 13-14, 2020
-
San Francisco, CA | Feb 26-27, 2020
-
Provider: ANSIAdd to CartPrice: $142
- Add to Cart
- Add to Cart
- Add to Cart
-
Provider: ANSIAdd to CartPrice: $120
-
Provider: ANSIAdd to CartPrice: $250
-
Provider: SEPTAdd to CartPrice: $299
- Add to Cart
-
Provider: Quality-Control-PlanAdd to CartPrice: $37
- Add to Cart
-
Provider: At-PQCAdd to CartPrice: $397
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
You Recently Viewed
